» Articles » PMID: 4357613

Induction of the Platelet Release Reaction by Phytohemagglutinin

Overview
Journal J Clin Invest
Specialty General Medicine
Date 1974 Jan 1
PMID 4357613
Citations 11
Authors
Affiliations
Soon will be listed here.
Abstract

We have previously shown that the erythroagglutinating phytohemagglutinin (E-PHA) from Phaseolus vulgaris binds to the surface of intact human platelets and that adenylate cyclase activity in the particulate fraction of E-PHA-treated platelets is lower than in comparable controls. We now find that E-PHA induces release of [(14)C]serotonin from platelets. Release follows binding of E-PHA, and a haptenic inhibitor of E-PHA binding prevents induction of release. E-PHA does not produce platelet lysis and has little effect on [(14)C]serotonin uptake. Platelets possess approximately 300,000 receptor sites of E-PHA per cell, and we estimate that about 15% of these sites must be occupied by E-PHA to initiate the release reaction. Prior incubation of platelets with prostaglandin E(1), theophylline, or dibutyryl cyclic AMP prevents E-PHA-induced release, although these agents have little effect on E-PHA binding to platelets. Thrombin and E-PHA produce different rates and extents of serotonin release. Thrombin (1 U/ml) causes release of 75-85% of platelet [(14)C]-serotonin, with half-maximal release occurring less than 0.5 min after thrombin addition. E-PHA, however, induces release of only 30-60% of platelet serotonin at a 10-fold slower rate. In addition, utilizing electron microscopy, we have observed striking differences in the morphological changes that occur in platelets exposed to E-PHA as compared with thrombin. Thus, the platelet release reaction may be triggered in part by binding of E-PHA to the cell surface, but this reaction only partially resembles that produced by thrombin.

Citing Articles

Isolation and quantitation of the platelet membrane glycoprotein deficient in thrombasthenia using a monoclonal hybridoma antibody.

McEver R, Baenziger N, MAJERUS P J Clin Invest. 1980; 66(6):1311-8.

PMID: 6449521 PMC: 371616. DOI: 10.1172/JCI109983.


The effects of thrombin on phytohemagglutinin receptor sites in human platelets.

FEAGLER J, TILLACK T, Chaplin D, MAJERUS P J Cell Biol. 1974; 60(3):541-53.

PMID: 4207395 PMC: 2109233. DOI: 10.1083/jcb.60.3.541.


Modulation of heparin cofactor II activity by histidine-rich glycoprotein and platelet factor 4.

Tollefsen D, Pestka C J Clin Invest. 1985; 75(2):496-501.

PMID: 3838317 PMC: 423524. DOI: 10.1172/JCI111725.


Inhibition of human platelet aggregation by monovalent antifibrinogen antibody fragments.

Tollefsen D, MAJERUS P J Clin Invest. 1975; 55(6):1259-68.

PMID: 1169259 PMC: 301881. DOI: 10.1172/JCI108045.


The perturbation of thrombin binding to human platelets by anions.

Shuman M, MAJERUS P J Clin Invest. 1975; 56(4):945-50.

PMID: 1159095 PMC: 301950. DOI: 10.1172/JCI108174.


References
1.
Weber T, NORDMAN C, Grasbeck R . Separation of lymphocyte-stimulating and agglutinating activities in phytohaemagglutinin (PHA) from Phaseolus vulgaris. Scand J Haematol. 1967; 4(1):77-80. DOI: 10.1111/j.1600-0609.1967.tb01601.x. View

2.
MAJERUS P, Smith M, Clamon G . Lipid metabolism in human platelets. I. Evidence for a complete fatty acid synthesizing system. J Clin Invest. 1969; 48(1):156-64. PMC: 322201. DOI: 10.1172/JCI105964. View

3.
KORNFELD R, Kornfeld S . The structure of a phytohemagglutinin receptor site from human erythrocytes. J Biol Chem. 1970; 245(10):2536-45. View

4.
Wolfe S, Shulman N . Inhibition of platelet energy production and release reaction by PGE1, theophylline and cAMP. Biochem Biophys Res Commun. 1970; 41(1):128-34. DOI: 10.1016/0006-291x(70)90478-x. View

5.
Okuda M, Nemerson Y . Transport of serotonin by blood platelets: a pump-leak system. Am J Physiol. 1971; 220(1):283-8. DOI: 10.1152/ajplegacy.1971.220.1.283. View